微环境T型钙通道调控神经元与胶质细胞过程促进胶质母细胞瘤生长
该研究将同系胶质母细胞瘤(GBM)细胞移植到Cav3.2敲除小鼠,发现微环境Cav3.2缺失显著减少肿瘤生长并延长生存;神经元Cav3.2促进胶质瘤干细胞生长及神经元/GBM功能性突触连接;Cav3阻断剂米贝地尔与替莫唑胺(TMZ)和放疗协同抑制肿瘤生长并延长生存。
要点
- 微环境Cav3.2敲除可减少GBM生长并延长动物生存。
- 神经元Cav3.2促进胶质瘤干细胞生长及神经元/GBM突触连接。
- 米贝地尔与TMZ和放疗协同增强抗GBM效果。
核心结论
- 微环境Cav3通过调控神经元和胶质细胞过程促进GBM进展。
- 米贝地尔靶向内在和微环境Cav3可增强TMZ和放疗的抗GBM效果。
研究设计与样本
- 将同系GBM细胞移植到Cav3.2敲除小鼠以评估微环境T型钙通道对GBM生长的作用。
- 将同系GBM细胞移植到海马Schaffer侧支区域并进行电生理记录。
- 用野生型和Cav3.2敲除小鼠神经元与胶质瘤干细胞共培养评估Cav3.2对突触连接和肿瘤细胞生长的影响。
- 对野生型和Cav3.2敲除小鼠肿瘤进行单细胞RNA测序以阐明微环境对肿瘤的调控。
主要发现
- 微环境Cav3.2敲除导致GBM生长显著减少并延长动物生存。
- 神经元Cav3.2在共培养中促进胶质瘤干细胞生长,并在体内促进神经元/GBM功能性突触连接。
- 单细胞RNA测序显示微环境Cav3.2调控神经元和胶质细胞生物学过程。
- 微环境Cav3.2下调GBM肿瘤中许多与少突胶质前体样细胞状态调控相关的基因。
- 用Cav3阻断剂米贝地尔处理胶质瘤干细胞可下调与神经元过程相关的基因。
关键数值与推荐
- Cav3阻断剂米贝地尔与替莫唑胺(TMZ)和放疗协同减少体内肿瘤生长并延长动物生存。
临床怎么用
- 米贝地尔作为FDA批准的药物再定位,可能成为GBM患者的新潜在疗法。
- 靶向内在和微环境Cav3可能增强TMZ和放疗的抗GBM效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma (GBM) is the most common primary malignant brain tumor. The aim of this study was to elucidate the role of microenvironment and intrinsic T-type calcium channels (Cav3) in regulating GBM. METHODS: We grafted syngeneic GBM cells into Cav3.2 knockout (KO) mice to assess the role of microenvironment T-type calcium channels on GBM growth. We grafted syngeneic GBM cells into the hippocampus along the Schaffer collaterals and performed electrophysiology. We used neurons from wild type (WT) and Cav3.2KO mice in co-culture with GBM stem cells (GSCs) to assess the effects of Cav3.2 on neuron/GSC synaptic connections and tumor cell growth. We performed single-cell RNA sequencing (scRNA-seq) of tumors from WT and Cav3.2KO mice to elucidate the regulation of tumors by the microenvironment. RESULTS: Cav3.2KO in the microenvironment led to significant reduction of GBM growth and prolongation of animal survival. Neuronal Cav3.2 promoted GSC growth in co-culture and neuron/GBM functional synaptic connections in vivo. scRNA-seq showed that microenvironment Cav3.2 regulates neuronal and glial biological processes. Microenvironment Cav3.2 downregulated numerous genes associated with regulating the oligodendrocyte precursor-like cell state in GBM tumors. Treatment of GSCs with the Cav3 blocker mibefradil downregulated genes associated with neuronal processes. The Cav3 blocker drug mibefradil synergized with temozolomide (TMZ) and radiation to reduce in vivo tumor growth and prolong animal survival. CONCLUSIONS: The data reveal a role for microenvironment Cav3 in promoting GBM progression through regulating neuronal and glial processes. Targeting both intrinsic and microenvironment Cav3 with the inhibitor mibefradil significantly enhanced the anti-GBM effects of TMZ and radiation. Glioblastoma (GBM) is the most common and deadliest human brain cancer. This study shows that calcium channels, known as T-type calcium channels (Cav3), promote GBM growth and malignancy by increasing the tumor-promoting functional connections between brain cells called neurons and GBM tumor cells. The study also shows that targeting Cav3 with an FDA-approved repurposed drug called mibefradil, which blocks the channels in neurons and GBM tumor cells, leads to inhibition of tumor growth. Mibefradil is therefore a new potential therapy for GBM patients.
引用
- Dube CJ, Zhang Y, Saha S, et al. Microenvironment T-type calcium channels regulate neuronal and glial processes in tumor cells to promote glioblastoma growth. Neuro Oncol. 2026. PMID: 42218829. doi:10.1093/neuonc/noag131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。